Since, β and γ-amino acids are non-proteinnogenic in nature and the BSBHps containing these amino acids showed better inhibitory activity than the tetra substituted α-amino acid (Aib) containing breaker peptides, these results can be used for designing Amylin agonists with better pharmacodynamic as well as pharmacokinetic profile that can be used for drug design against T2DM. The gene discussed is IAPP; the disease is type 2 diabetes mellitus.